FDA OKs Trastuzumab Deruxtecan for Earlier Use in Breast Cancer

With a standard approval from the FDA, the HER2-directed antibody drug conjugate can now be used earlier in treatment to delay disease progression.
FDA Approvals
With a standard approval from the FDA, the HER2-directed antibody drug conjugate can now be used earlier in treatment to delay disease progression.
FDA Approvals